AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

IBRX · NASDAQ · Biotechnology

ImmunityBio

Commercializes ANKTIVA while developing cytokine, NK-cell, and vaccine immunotherapies for cancer.

$8.07

After-hours close+0.02 (+0.25%)

At close$8.05(−4.17%)

Something off on this page? Send us feedback.

Profile

ImmunityBio, Inc.IBRXHealth Care

Commercializes ANKTIVA, an IL-15 receptor agonist used with BCG for certain non-muscle-invasive bladder cancers, while developing it across more cancer settings alongside NK-cell therapies and adenovirus-vectored vaccines. Product revenue is concentrated in ANKTIVA, whose bladder-cancer use depends on BCG availability.

Commercializes ANKTIVA, an IL-15 receptor agonist administered with BCG for BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ. Commercial activity remains centered in the United States, while approvals and distribution partnerships extend access across Europe, the Middle East, and parts of Asia.

Builds its Cancer BioShield pipeline around ANKTIVA, off-the-shelf and autologous NK-cell therapies, adenovirus-vectored vaccines, and other immune-response modulators for solid and blood cancers. Internal research and manufacturing sites work alongside affiliated facilities and contract manufacturers to advance and supply these programs. Product revenue remains concentrated in ANKTIVA; its bladder-cancer use requires co-administration with BCG, and the capital structure includes a related-party convertible note and revenue-interest obligation.

Company facts

CEORichard Gerald Adcock

ListedJul 28, 2015

ExchangeNASDAQ

HeadquartersSan Diego, CA

CountryUnited States

Employees691

CIK0001326110

ISINUS45256X1037

Key statistics

Market cap$8.43B

EPS (ttm)−$0.9736

P/E (ttm)−8.27

ROE135.0%

P/B−8.08

P/S50.85

Dividend yield—

Beta1.68vs XLV 0.09

Year to date +299% · Average volume (30d) 8.7M

Analysts

Price target, next 12 months$12.00+49.1%Median of 5 analysts · vs the Aug 28 close

ConsensusBuy5 of 5 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $8.05

High$12.00+49.1%

Median$12.00+49.1%

Low$12.00+49.1%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior rating	Rating	Prior target	Target
May 8, 2026	BTIG	Target			$6	$12
Mar 4, 2026	Piper Sandler	Reiterate		Overweight	$7	$12
Feb 23, 2026	H.C. Wainwright	Target				$15
Jan 20, 2026	Piper Sandler	Reiterate		Overweight		$7
May 20, 2025	Piper Sandler	Upgrade	Neutral	Overweight

Earnings

EPS

Estimate−$0.08

ReportedDue Nov 3, 2026

Revenue

Estimate$59.2M

ReportedDue Nov 3, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 4, 2026Q2 FY26	−$0.08	−$0.22	−175.0%	$49.7M	$51.2M	+3.1%	−2.80%
May 7, 2026Q1 FY26	−$0.08	−$0.09	−12.5%	$43.1M	$44.2M	+2.6%	+9.66%
Feb 23, 2026Q4 FY25	−$0.08	−$0.06	+25.0%	$38.4M	$38.3M	−0.2%	+17.50%
Nov 4, 2025Q3 FY25	−$0.10	−$0.07	+30.0%	$37.8M	$32.1M	−15.1%	+3.37%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$16.5M	$26.4M	$32.1M	$38.3M	$44.2M	$51.2M
Gross profit	$16.5M	$26.3M	$27.9M	$34.0M	$44.0M	$50.9M
Operating income	−$64.4M	−$71.3M	−$55.6M	−$64.7M	−$69.8M	−$61.7M
Net income	−$129.6M	−$92.6M	−$67.3M	−$61.9M	−$632.8M	−$230.4M
Diluted EPS	−$0.15	−$0.10	−$0.07	−$0.06	−$0.62	−$0.22
Gross margin	99.6%	99.5%	87.1%	88.9%	99.5%	99.4%
Operating margin	-390.1%	-269.8%	-173.5%	-169.0%	-157.9%	-120.4%

Fiscal years (4-quarter sums)FY21 $934.0K · FY22 $240.0K · FY23 $622.0K · FY24 $14.7M · FY25 $113.3M

Revenue by product · Q2 FY26

Product$50.7M · 99%

Product And Service, Other$568.0K · 1%

Revenue by geography · Q2 FY26

United States$50.7M · 99%

Europe$518.0K · 1%

Balance sheet, Jun 30, 2026Cash & short-term investments $357.4M · Total debt $813.1M · Total assets $628.5M · Shareholders' equity −$1.05B

Dividends

No dividends on record.

Ownership

Institutions 19.86%208.02M sharesInsiders 27.18%284.68M sharesOther 52.96%554.65M shares

Shares outstanding 1.05B · Float 113.84M · 10.9% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Patrick Soon-Shiong	745.52M	64.80%	13D	Aug 6, 2026
Patrick Soon-Shiong · director, 10 percent owner, officer: See remarks	280.78M	26.81%	Form 4	Apr 2, 2026
BlackRock, Inc.	34.08M	3.25%	13F	Aug 7, 2026
State Street Corp	21.40M	2.04%	13F	Aug 7, 2026
Vanguard Portfolio Management LLC	17.86M	1.71%	13F	Aug 13, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Jul 1, 2026	Christobel Selecky	director	−159,478	$9.02
Jul 2, 2026	Cheryl Cohen	director	−131,210	$9.50
Jun 29, 2026	Christobel Selecky	director	−95,722	$9.01
Jun 30, 2026	Christobel Selecky	director	−1,000	$9.00
Jun 24, 2026	Barry J. Simon	director	−25,000	$7.88